This was discussed at the Portfolio Committee and Steering Committee and there will be no changes to the Portfolio inclusion criteria. There are be special consideration for trials that do not meet our criteria, which have not been used to date. What happens if perform well and their NCC underperforms (i.e., doesn’t make their baseline)? No one will be penalized if they are performing well. 3CTN hopes to discuss with NCC and NACC leads to understand how funding will be distributed given that circumstance. For sustainability, we need to understand how to capture impact. Who does it impact –currently using accrual– but what about publications or patients are we able to collect it now to have an – idea? 3CTN aims to try to get as much information as possible. We are attempting to commit to collecting publication information either through clinicaltrials.gov or the sponsors/PI themselves to see what the data means from an impact perspective. NETWORK ACCOMPLISHMENTS & PROPOSED STRATEGIC PLAN HIGHLIGHTS Q-CROC Annie Morin, Resource for Academic Clinical Research, CIUSSS de L'Estrie- CHUS Key topics discussed: Overview of Site Structure; Goals and Objectives; Activity Metrics & Challenges Questions: What worked the best for you to motivate sites to increase recruitment? PCF was a strong motivation for the sites, and the PI being aware increased awareness – but we also worked on putting tools in place to make PIs aware which protocols are in place or open to recruitment. CancerCare Manitoba Kathryn Dyck, Manager Clinical Trials Unit, CancerCare Manitoba Key topics discussed: Overview, and Objectives Progress, Activity Metrics & Challenges and Beyond 2018 Ontario Network Regional Coordinating Centre Dr. Glenn Bauman, PI, London Regional Cancer Program & Chair, Ontario Leadership Council Key topics discussed: Overview on NCC/NRCC/NACC structure; Goals and Objective; Challenges and Next Steps Questions: Could there be a collaborative effort in creating a national website that is user friendly for patients and mobile friendly listing all Canadian clinical trials? General agreement that it would be useful to approach this as a national initiative. BC Cancer Agency Network Regional Coordinating Centre Dr. Bernie Eigl, Medical Director, Provincial Clinical Trials Key topics discussed: Overview and Organizational Structure; Provincial Performance; Centre Performance; Strengths and Challenges beyond 2018
This was discussed at the Portfolio Committee and Steering Committee and there will be no changes to the Portfolio inclusion criteria. There are be special consideration for trials that do not meet our criteria, which have not been used to date. What happens if perform well and their NCC underperforms (i.e., doesn’t make their baseline)? No one will be penalized if they are performing well. 3CTN hopes to discuss with NCC and NACC leads to understand how funding will be distributed given that circumstance. For sustainability, we need to understand how to capture impact. Who does it impact –currently using accrual– but what about publications or patients – are we able to collect it now to have an idea? 3CTN aims to try to get as much information as possible. We are attempting to commit to collecting publication information either through clinicaltrials.gov or the sponsors/PI themselves to see what the data means from an impact perspective. NETWORK ACCOMPLISHMENTS & PROPOSED STRATEGIC PLAN HIGHLIGHTS Q-CROC Annie Morin, Resource for Academic Clinical Research, CIUSSS de L'Estrie- CHUS Key topics discussed: Overview of Site Structure; Goals and Objectives; Activity Metrics & Challenges Questions: What worked the best for you to motivate sites to increase recruitment? PCF was a strong motivation for the sites, and the PI being aware increased awareness – but we also worked on putting tools in place to make PIs aware which protocols are in place or open to recruitment. CancerCare Manitoba Kathryn Dyck, Manager Clinical Trials Unit, CancerCare Manitoba Key topics discussed: Overview, and Objectives Progress, Activity Metrics & Challenges and Beyond 2018 Ontario Network Regional Coordinating Centre Dr. Glenn Bauman, PI, London Regional Cancer Program & Chair, Ontario Leadership Council Key topics discussed: Overview on NCC/NRCC/NACC structure; Goals and Objective; Challenges and Next Steps Questions: Could there be a collaborative effort in creating a national website that is user friendly for patients and mobile friendly listing all Canadian clinical trials? General agreement that it would be useful to approach this as a national initiative. BC Cancer Agency Network Regional Coordinating Centre Dr. Bernie Eigl, Medical Director, Provincial Clinical Trials Key topics discussed: Overview and Organizational Structure; Provincial Performance; Centre Performance; Strengths and Challenges beyond 2018
Canadian%20Cancer%20Clinical%20Trials%20Network%20Minutes%20FINAL%20For%20Website.docx